SCHEMBL6885339

SCHEMBL6885339

CC(C)(C)c1cc(C(C)(C)C)cc(C(C)(C)Sc2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPN P05981 1/20 0.66
MAPT P10636 1/20 0.66
ALOX15 P16050 1/20 0.66
SIRT5 Q9NXA8 1/20 0.66
CA2 P00918 3/20 0.47
CA1 P00915 2/20 0.47
ALDH1A1 P00352 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
POLB P06746 1/20 0.45
TYR P14679 1/20 0.45
VCAM1 P19320 12/20 0.44
GABRA1 P14867 1/20 0.43
GABRB2 P47870 1/20 0.43
HSP90AA1 P07900 1/20 0.38
MEN1 O00255 1/20 0.38
GALR3 O60755 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4996488 0.87 ALOX15 (0.81) HPNMAPTALOX15SIRT5CA2
SCHEMBL6439618 0.83 HPN (0.62) HPNMAPTALOX15SIRT5CA2
Probucol SCHEMBL5143451 0.80 HPN (1.00) HPNMAPTALOX15SIRT5CA2
Probucol SCHEMBL4150 0.80 HPN (1.00) HPNMAPTALOX15SIRT5CA2
SCHEMBL11290856 0.79 ALOX15 (0.53) HPNMAPTALOX15SIRT5CA2
Probucol SCHEMBL4620631 0.78 ALOX15 (0.95) HPNMAPTALOX15SIRT5CA2
SCHEMBL9506457 0.78 HPN (0.79) HPNMAPTALOX15SIRT5CA2
Probucol SCHEMBL8344652 0.78 ALOX15 (0.95) HPNMAPTALOX15SIRT5CA2
SCHEMBL35141 0.77 CA2 (0.67) HPNMAPTALOX15SIRT5CA2
SCHEMBL21241542 0.76 HPN (0.76) HPNMAPTALOX15SIRT5CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040266879-A1 Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality ATHEROGENICS, INC. 2004-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266879-A1 Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality HDLBP, CETP, APOB HPN 156/4885MAPT 3841/4885ALOX15 1587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.